Evidence map›Paper›PMID 33007353›Full record

ArticleProgress in cardiovascular diseases

Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.

Ileana L Piña, Jinwei Yuan, Gail Ackourey, Hector Ventura

Abstract read
PubMed Publisher
In one paragraph

Article in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ileana L PiñaWayne State University, Detroit, MI, USA. Electronic address: ilppina@aol.com.
Jinwei YuanRelypsa, Inc., a Vifor Pharma Company, Redwood City, CA, USA.
Gail AckoureyRelypsa, Inc., a Vifor Pharma Company, Redwood City, CA, USA.
Hector VenturaDepartment of Cardiology, Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA, USA.
Vifor Pharma (United States) · USOchsner Medical Center · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperkalemia (HK) is a serious medical condition that can cause potentially fatal cardiac arrhythmias. Patients with heart failure (HF) are at risk of HK due to underlying chronic kidney disease and use of guideline-recommended renin-angiotensin-aldosterone system inhibitors. Patiromer, a sodium-free, non-absorbed potassium (K

objectiveTo evaluate the consistency of patiromer's effect on lowering serum K

methodsThis post-hoc analysis evaluated the efficacy and safety of patiromer for management of HK over a 4-week treatment period using combined data from three clinical trials (AMETHYST-DN, OPAL-HK and TOURMALINE). Eligible patients had HK (serum K

resultsIn total, 653 patients who received ≥1 dose of patiromer were evaluable for efficacy (214 diagnosed with HF and 439 without HF). Mean baseline serum K

conclusionsIn this pooled analysis of patients with HK, patiromer was generally well tolerated and reduced serum K

Indexed as

AgedAged, 80 and overBiomarkersChelating AgentsDown-RegulationFemaleHeart FailureHumansHyperkalemiaMaleMiddle AgedPolymersPotassiumRandomized Controlled Trials as TopicTreatment OutcomeBiomarkersChelating AgentspatiromerPolymersPotassiumHeart failureHyperkalemiaPatiromerPotassium binderRAAS inhibitor

Identifiers

PMID33007353
OpenAlexW3090042183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.